Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SB 313 xTZ

Drug Profile

SB 313 xTZ

Alternative Names: SB-313; SB-313-xTZ; Zetakine engineered T-cell therapy - Sangamo

Latest Information Update: 12 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Sangamo BioSciences
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action T-cell receptor gene stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 22 Mar 2016 Discontinued - Phase-I for Glioblastoma (Combination therapy, Recurrent, Refractory metastatic disease) in USA (Intracerebral)
  • 08 Jan 2015 Sangamo Biosciences in-licenses nanoparticle technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top